|Description||CUDC-101 is a multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential antineoplastic activity. HDAC/EGFR/HER2 inhibitor CUDC-101 inhibits the activity of these three enzymes but the exact mechanism of action is presently unknown. This agent may help overcome resistance to inhibition of EGFR and Her2 through a simultaneous, synergistic inhibition of EGFR, Her2, and HDAC.|
|Current Developer||Curis Inc.|
Tacedinaline, also known as CI-944, is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits his...
NCC149 is a potent and selective histone deacetylase 8 (HDAC8) inhibitor.
CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respecti...
MI-192 is a selectively histone deacetylases inhibitor (HDACs) that preferentially inhibits HDAC2 with IC50 value of 30 nM and HDAC3 with IC50 value of 16 nM ov...
Mocetinostat is a rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activi...
Resminostat is an inhibitor of histone deacetylase (HDAC) with IC50 values of 42.5nM, 50.1nM and 71.8nM, respectively against HDAC1, 3 and 6. As an inhibitor of...
UF-010 is a Class I HDAC inhibitor, inhibiting proliferation of a range of cancer cell lines.
PTACH is a SAHA-based novel inhibitor of histone deacetylase (HDAC). It exerts potent growth inhibition against various human cancer cells, with EC50 values ran...
Abexinostat, also known as PCI-24781 or CRA-024781, is novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antine...
Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8. Droxinostat shows comparable inhibition of HDAC6 and HDAC8 (IC50 = 2.47 and 1.46 μmol/L, respec...
RGFP 109 is a histone deacetylase (HDAC) inhibitor that has shown to reverse FXN gene silencing in short-term studies of Friedreich ataxia (FRDA) patient cells.
M344 is a potent HDAC inhibitor, which can also induced expression of the pro-apoptotic genes, Puma and Bax, together with the morphological features of apoptos...
Sirtinol is a SIRT inhibitor. Sirtinol significantly increased the acetylation of p53, which has been reported to be a target of SIRT1/2. Sirtinol significantly...
Givinostat (INN) or gavinostat, aslo known as ITF2357, is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic...
4SC-202 is a selective and potent, orallly available inhibitor of histone deacetylases (HDAC) specific for class 1 HDAC isoenzymes, with IC50 of 1.20 μM, 1.12 μ...
Sodium butyrate is the sodium salt of butyric acid, used in the culture of mammalian cells.
The hydrochloride salt form of Tinostamustine, a benzimidazol derivative, has been found to be a HDAC inhibitor and could probably be effective against sorts of...
TC-H 106 is a slow, tight-binding inhibitor of class I HDAC, including HDAC 1, 2, and 3 with IC50 values of 150 nM , 760nM, and 370 nM, respectively. It demonst...
Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects.